1 7
A P P L I C A T I O N N O T E
21. Ni, Y., Lempp, F.A., Mehrle, S., Nkongolo, S., Kaufman, C., Fälth, M., Stindt, J., Königer, C., Nassal, M., Kubitz, R., Sült-
mann, H., & Urban, S. (2014). Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for
species-specific entry into hepatocytes. Gastroenterology, 146 4, 1070-83.
22. Li, Y., Zhou, J., & Li, T. (2022). Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment.
Frontiers in Molecular Biosciences, 9.
23. Calabria, Andrew C., et al. "GLP-1 Receptor Antagonist Exendin-(9-39) Elevates Fasting Blood Glucose Levels in Con-
genital Hyperinsulinism Owing to Inactivating Mutations in the ATP-Sensitive K+ Channel." Diabetes, vol. 61, no. 10, Oct.
2012, pp. 2585–91, https://doi.org/10.2337/db12-0166.
24. Coddou, C., Sandoval, R., Hevia, M., & Stojilkovic, S. (2019). Characterization of the antagonist actions of 5-BDBD at
the rat P2X4 receptor. Neuroscience Letters, 690, 219-224. https://doi.org /10.1016/j.neulet.2018.10.047.
25. Bidula, S., Nadzirin, I., Cominetti, M., Hickey, H., Cullum, S., Searcey, M., Schmid, R., & Fountain, S. (2021). Structural
Basis of the Negative Allosteric Modulation of 5-BDBD at Human P2X4 Receptors. Molecular Pharmacology, 101, 33 - 44.
https://doi.org /10.1124/molpharm.121.000402.
© 2025 NanoTemper Technologies, GmbH, Munich, Germany. All Rights Reserved.
NativeMP
TM
is a registered trademark of Cube Biotech, GmbH.
All third-party trademarks are the property of their resepctive owners.
